Ceva Completes Deal to Acquire Portfolio of Merial Swine and Cattle Vaccines and Nonsteroidal Anti-inflammatories from Boehringer Ingelheim

Food and Healthcare Press Releases Friday January 20, 2017 10:34
LIBOURNE, France--20 Jan--PRNewswire/InfoQuest

Ceva Sante Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health.

All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply.
Ceva has been consistently one of the fastest growing top 10 veterinary businesses in the last decade, investing heavily in the development of vaccines, as part of its global preventative health strategy.
Commenting on the deal, Ceva Chairman & CEO Dr. Marc Prikazsky said:

"We are delighted to acquire this range of products and strong pipeline of R&D assets.   The knowhow behind these products dates from Pasteur, Rhone-Merieux, Merial and now as Ceva we are conscious that we have a responsibility to maintain this strong veterinary scientific tradition.   Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow."

ABOUT CEVA SANTE ANIMALE

Ceva Sante Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde). Ceva Chairman and CEO is Marc Prikazsky.

Website: http://www.ceva.com
PRESS CONTACT
Martin Mitchell
Communication Director
+33-05-57-55-40-80
martin.mitchell@ceva.com
Company: Davidson Ryan Dore
Lawrence Dore
Lawrence.dore@drdpartnership.com
Phone: +44(0)207-520-9218
Source: Ceva Sante Animale

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics